全文获取类型
收费全文 | 5695篇 |
免费 | 456篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 49篇 |
儿科学 | 119篇 |
妇产科学 | 101篇 |
基础医学 | 671篇 |
口腔科学 | 67篇 |
临床医学 | 765篇 |
内科学 | 1163篇 |
皮肤病学 | 93篇 |
神经病学 | 473篇 |
特种医学 | 162篇 |
外科学 | 979篇 |
综合类 | 45篇 |
一般理论 | 3篇 |
预防医学 | 502篇 |
眼科学 | 86篇 |
药学 | 428篇 |
中国医学 | 7篇 |
肿瘤学 | 448篇 |
出版年
2023年 | 57篇 |
2022年 | 44篇 |
2021年 | 317篇 |
2020年 | 180篇 |
2019年 | 243篇 |
2018年 | 269篇 |
2017年 | 190篇 |
2016年 | 165篇 |
2015年 | 250篇 |
2014年 | 256篇 |
2013年 | 364篇 |
2012年 | 461篇 |
2011年 | 490篇 |
2010年 | 236篇 |
2009年 | 164篇 |
2008年 | 291篇 |
2007年 | 278篇 |
2006年 | 298篇 |
2005年 | 216篇 |
2004年 | 206篇 |
2003年 | 185篇 |
2002年 | 156篇 |
2001年 | 80篇 |
2000年 | 65篇 |
1999年 | 63篇 |
1998年 | 33篇 |
1997年 | 30篇 |
1996年 | 31篇 |
1995年 | 31篇 |
1994年 | 12篇 |
1993年 | 20篇 |
1992年 | 44篇 |
1991年 | 41篇 |
1990年 | 41篇 |
1989年 | 33篇 |
1988年 | 28篇 |
1987年 | 27篇 |
1986年 | 24篇 |
1985年 | 32篇 |
1984年 | 27篇 |
1983年 | 12篇 |
1979年 | 15篇 |
1978年 | 9篇 |
1974年 | 11篇 |
1973年 | 13篇 |
1971年 | 13篇 |
1970年 | 12篇 |
1968年 | 14篇 |
1967年 | 8篇 |
1966年 | 13篇 |
排序方式: 共有6161条查询结果,搜索用时 15 毫秒
51.
52.
53.
Pichard C Kyle UG Slosman DO Penalosa B 《Clinical nutrition (Edinburgh, Scotland)》1996,15(3):109-114
Anorexia nervosa (AN) is associated with a reduced metabolically active fat-free mass (FFM) and basal metabolic rate (BMR). Excessive refeeding results in major fat deposition which is not well tolerated by patients. Prediction of BMR is, therefore, a clinical issue during refeeding, but measurement by indirect calorimetry is time-consuming and not widely available. The study aim was to determine if and when BMR could be estimated from prediction formulas based on FFM derived from bioelectrical impedance analysis (BIA) in AN patients during refeeding. Indirect calorimetry and BIA were prospectively measured bi-weekly in 9 AN patients (body mass index 13.7 +/- 0.5 kg/m2) for 10 weeks of refeeding. Initial BMR was 969 +/- 46.7 kcal/d and 27.7 +/- 1.4 kcal/kg FFM, and at week 10 increased to 1360 +/- 44.6 kcal/d and 35.8 +/- 0.8 kcal/kg FFM. While correlations improved with increasing weight, FFM and body mass index, prediction formulas are insufficient to permit prediction of BMR based on weight or FFM, even after 10 weeks of refeeding. To allow for optimal nutritional support, indirect calorimetry measurements may be useful in the early weeks of refeeding because of a large variability of basal metabolic rate between patients. 相似文献
54.
Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. 总被引:19,自引:0,他引:19
C S Debes-Marun G W Dewald S Bryant E Picken R Santana-Dávila N González-Paz J M Winkler R A Kyle M A Gertz T E Witzig A Dispenzieri M Q Lacy S V Rajkumar J A Lust P R Greipp R Fonseca 《Leukemia》2003,17(2):427-436
The nonrandom recurrent nature of chromosome abnormalities in myeloma suggests a role for them in disease pathogenesis. We performed a careful cytogenetic analysis of patients with abnormal karyotypes (n = 254), to discern patterns of association, search for novel abnormalities and elucidate clinical implications. Patients with karyotypic abnormalities suggestive of myelodysplasia/acute leukemia were excluded. In this study we compared survival by abnormality only between patients with abnormal karyotypes. Patients with abnormalities were more likely to have features of aggressive disease as compared to all other patients without abnormalities entered into the myeloma database (lower hemoglobin, higher beta(2)-microglobulin, labeling-index and plasmocytosis; all P < 0.0001). Several groups of patients could be readily identified; hypodiploid (22%), pseudodiploid (36%), hyperdiploid (31%) and near-tetraploid (11%). Clustering associations were seen among several trisomies and monosomy of chromosome 13 and 14. Several monosomies (-2, -3, -13, -14 and -19), 1p translocations/ deletions, and hypodiploidy were associated with a significantly shorter survival. Trisomy of chromosome 13 was rare ( <2%). Even among patients with abnormal karyotypes, specific chromosome abnormalities can impart biologic variability in myeloma, including several monosomies, hypodiploidy and abnormalities of 1p. 相似文献
55.
Shaji Kumar S Vincent Rajkumar Robert A Kyle Martha Q Lacy Angela Dispenzieri Rafael Fonseca John A Lust Morie A Gertz Philip R Greipp Thomas E Witzig 《Journal of clinical oncology》2005,23(24):5668-5674
PURPOSE: Monoclonal gammopathy of undetermined significance (MGUS) progresses to multiple myeloma or another related plasma cell disorder (PCD) at a rate of approximately 1% per year. Identification of patients with MGUS at high risk of progression will allow development of preventive strategies. We studied the prognostic value of circulating plasma cells (PCs) in patients with MGUS to predict progression. PATIENTS AND METHODS: Patients were eligible for this retrospective analysis if they were seen at the Mayo Clinic between 1984 and 1997, were diagnosed with MGUS, and had an analysis of the peripheral blood for circulating PCs by the slide-based immunofluorescence method. Patients were observed for progression to another PCD. RESULTS: Three hundred twenty-five patients were eligible and 63 (19%) had circulating PCs. Patients with circulating PCs were twice as likely (hazard ratio, 2.1) to experience progression to another PCD (most commonly myeloma), compared with those without circulating PCs (95% CI, 1.1 to 4.3; P = .03). In patients with circulating PCs, the median progression-free survival was 138 months compared with a median not yet reached for those without circulating PCs (P = .028). The median overall survival also was shorter for those with circulating PCs. Other factors with prognostic value were high levels of M protein and non-immunoglobulin G heavy-chain type. CONCLUSION: The presence of circulating PCs, especially when combined with other known prognostic factors such as M protein concentration and immunoglobulin isotype, identify a group of individuals with MGUS at higher risk of progression to overt multiple myeloma. 相似文献
56.
57.
58.
S. Alex Marshall Kyle H. McKnight Allyson K. Blose Donald T. Lysle Todd E. Thiele 《Journal of neuroimmune pharmacology》2017,12(2):249-259
Excessive ethanol consumption alters the neuroimmune system and particularly impacts the cytokine milieu of the CNS. Cytokine dysregulation has been shown to underlie addictive-like behaviors including alcohol abuse; however, many studies focus primarily on the proinflammatory cytokine profile during alcohol dependence. The current study furthers this research by determining the impact of excessive ethanol consumption on interleukin-10 (IL-10) and interleukin-4 (IL-4) activity in a model of non-dependent binge consumption called the “drinking in the dark” (DID) paradigm. Furthermore, the ability of IL-10 to modulate ethanol consumption was tested using site-directed pharmacology. Immunohistochemistry analyses determined that ethanol decreased IL-10 by 50 % in the basolateral amygdala (BLA) but had no effect on IL-4. Neither IL-10 nor IL-4, however, were altered in the central amygdala (CEA). Enzyme linked immunosorbent assays confirmed that IL-10 was decreased in the amygdala but not in the serum, suggesting changes of this cytokine with the DID paradigm are restricted to the central nervous system. Finally, bilateral infusions of IL-10 into the BLA, but not CeA, reduced binge-like drinking and corresponding blood ethanol concentrations without impacting either locomotor activity or anxiety-like behavioral correlates. Together, these data support the idea that alcohol abuse dysregulates specific anti-inflammatory cytokines; however, ameliorating alcohol-induced effects on cytokines, like IL-10, may prove to be an effective therapy in curbing excessive consumption. 相似文献
59.
Stefan R. Jibodh Ran Schwarzkopf Shawn G. Anthony Henrik Malchau Kyle E. Dempsey Daniel M. Estok II 《The Journal of arthroplasty》2013
Despite the increasing volume of revision total hip arthroplasty (THA) being performed in the United States, there are few studies reporting mid-term clinical and radiographic outcomes of modular fully porous-coated femoral stems. We retrospectively studied a consecutive series of patients who underwent revision THA with a modular extensively porous-coated femoral component at a single institution and by a single surgeon. The final study group included 54 hips (52 patients) followed for an average of 84 months. Ten-year survival rates with revision for any reason and revision for femoral loosening as endpoints were 94% and 100%, respectively. No complications regarding the modular junction were encountered. Of the 50 hips with adequate radiographs, all showed proximal ingrowth and 42 (84%) had both proximal and distal ingrowth. The modular, fully porous-coated femoral stem studied demonstrated excellent survivorship and bone ingrowth at mid-term follow up. 相似文献
60.
PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS 下载免费PDF全文
Gilberto S. Almeida Carlo M. Bawn Martin Galler Ian Wilson Huw D. Thomas Suzanne Kyle Nicola J. Curtin David R. Newell Ross J. Maxwell 《NMR in biomedicine》2017,30(9)
Poly(adenosine diphosphate ribose) polymerases (PARPs) are multifunctional proteins which play a role in many cellular processes. Namely, PARP1 and PARP2 have been shown to be involved in DNA repair, and therefore are valid targets in cancer treatment with PARP inhibitors, such as rucaparib, currently in clinical trials. Proton magnetic resonance spectroscopy (1H‐MRS) was used to study the impact of rucaparib in vitro and ex vivo in liver tissue from mice, via quantitative analysis of nicotinamide adenosine diphosphate (NAD+) spectra, to assess the potential of MRS as a biomarker of the PARP inhibitor response. SW620 (colorectal) and A2780 (ovarian) cancer cell lines, and PARP1 wild‐type (WT) and PARP1 knock‐out (KO) mice, were treated with rucaparib, temozolomide (methylating agent) or a combination of both drugs. 1H‐MRS spectra were obtained from perchloric acid extracts of tumour cells and mouse liver. Both cell lines showed an increase in NAD+ levels following PARP inhibitor treatment in comparison with temozolomide treatment. Liver extracts from PARP1 WT mice showed a significant increase in NAD+ levels after rucaparib treatment compared with untreated mouse liver, and a significant decrease in NAD+ levels in the temozolomide‐treated group. The combination of rucaparib and temozolomide did not prevent the NAD+ depletion caused by temozolomide treatment. The 1H‐MRS results show that NAD+ levels can be used as a biomarker of PARP inhibitor and methylating agent treatments, and suggest that in vivo measurement of NAD+ would be valuable. 相似文献